Skip to content

Anxiolytic and Analgesic Effects of Melatonin

Anxiolytic and Analgesic Effects of Melatonin: A Randomized, Double-blinded, Placebo-controlled Clinical Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02386319
Acronym
ANAN-Melatonin
Enrollment
36
Registered
2015-03-11
Start date
2016-08-31
Completion date
2021-04-30
Last updated
2021-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety

Keywords

Melatonin, Surgery, Pharmacokinetic, Anxiolytic

Brief summary

The study's main objective is to investigate melatonin's anxiolytic and sleep-regulating effects in patients undergoing surgery. Moreover, the investigators intend to investigate the pharmacokinetic parameters of melatonin in this patient population.

Detailed description

The study is separated into two parts. In the first part the patients are undergoing cosmetic breast surgery, and in the second part the patient undergo inguinal og umbilical surgery. The first part is a cohort at 12 patients undergoing breast surgery. All patients in this group will be treated with melatonin, and the investigators intend to investigate the pharmacokinetic parameters of melatonin. Melatonin will be administrated 60 min. before surgery and the evening after surgery at 9 pm. All patients will receive an intravenous catheter. The intravenous catheter will be used for blood sampling. A baseline blood sample will be taken 65 min before surgery (baseline) and thereafter blood samples will be obtained 0 min., 15 min., 30 min., 45 min., 60 min., 90 min., 120 min., 180 min., 240 min., 300 min., 360 min. and 420 min. after administration of melatonin. Blood samples will be obtained again after administration of melatonin at 9 pm. in the evening in the same manner as described above. Plasma samples will be stored at minus 80 C and analyzed at the research laboratory of the Department of surgery, Herlev Hospital. The analysis will be preformed with the RIA-technique. The second part is a randomized, double-blind, placebo-controlled study with a total of 32 participants divided into a intervention group (16) and a placebo group (16). In this part the investigators intend to investigate the anxiolytic and sleep-promoting effects of melatonin. Melatonin and placebo will be administrated at 9 pm. the evening before surgery, 120 min. before surgery, immediately after surgery in the PACU and at 9 pm the evening after surgery. Anxiety will be measured by the State-Trait Anxiety Inventory (STAI) and a VAS-scale (0 mm = no anxiety and 100 mm = worst anxiety). Quality of sleep will be measured at the VAS-scale as well (0 mm = best sleep and 100 = worst sleep). Randomization will be performed by a computer at randomization.com. The first generator function is used. The randomization will be preformed in blocks of 4 patients in each. Manufacturing of medications and randomization will be made by an independent pharmacist. The primary outcome is preoperative anxiety as measured on the STAI. A previous study investigated preoperative anxiety before hernia surgery and found a mean of 35.4 (SD 10.0) on the STAI scale. There does not exist any generally accepted measure of how large a change on the STAI scale constitutes a clinically important difference. However, a change equal to one standard deviation has been suggested. In the present study, this corresponds to a minimal relevant difference (MIREDIF) of 10 points on the STAI scale or 28%. A power of 80% was defined, a significance level of 5% and a minimal relevant difference (MIREDIF) of 28%. From these assumptions, 16 patients in each treatment group is needed Statistics Anxiety and sleep quality will be compared at individual timepoints between groups Comparison will be performed either by Mann-whitheys-test or unpaired t-test, depending on the distribution of data. Values are considered significant at a p-value at 5% or less. Data will be reported as mean (SD) or median (IQR) depending on the distribution of data. Data for the blood samples will be presented as AUC plasma concentrations, half-life, maximum concentration and time to maximum concentration.

Interventions

DRUGMelatonin

Gelatin capsules

DRUGPlacebo

Placebo capsules

Sponsors

Herlev Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

part one: * Patients who are candidates for breast surgery. * BMI between 18 and 30 * Visible veins in the elbow region * Fertile women use anti-contraception and have performed a negative pregnancy test

Exclusion criteria

part one: * Patients, who use daily opioids, benzodiazepines or melatonin * Patients diagnosed with a psychiatric disorder (defined as in medical treatment) * Patients with severe physical disease (ASA 3-4) * Patients with previous or ongoing alcohol or drug abuse * Patients with liver disease (defined as in medical treatment) * Patients diagnosed sleep disturbances * Patients who are unable to cooperate according to the protocol * Patients with allergy to melatonin Inclusion Criteria part two: \- Male patients who are candidates for inguinal or umbilical hernia reapir

Design outcomes

Primary

MeasureTime frameDescription
Preoperative Anxiety60 minutes preoperativeThe State scale of the State-Trait Anxiety Inventory (STAI). Construct: Current level of anxiety. Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).

Secondary

MeasureTime frameDescription
Pre- and Postoperative Anxietyat the preoperative interview, 60 minutes prior to surgery, 1 and 4 hours postoperatively.Visual analog scale
Intraoperative Requirement of Remifentanilintraopeativeµg/kg/min
Intraoperative Requirement of Propofolintraoperativemg/kg/min
Use of Rescue-opioids in the PACU0-24 hours postoperativedose
Postoperative Anxietyat the preoperative interview, 60 minutes prior to surgery and 4 hours postoperatively.State-Trait Anxiety Index
Perioperative Sleep Quality24 hoursVisual analog scale
General Well-being and Fatigue24 hoursVisual analog scale
Plasma Concentrations of Melatoninbaseline, 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, 360 min and 420 min. after melatonin administration.pg/ml
Use of Rescue-opioids in the Ward0-24 hours postoperativedose

Countries

Denmark

Participant flow

Participants by arm

ArmCount
Melatonin
Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery. Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery. Melatonin: Gelatin capsules
18
Placebo
Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery. Placebo: Placebo capsules
18
Total36

Baseline characteristics

CharacteristicMelatoninPlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
5 Participants6 Participants11 Participants
Age, Categorical
Between 18 and 65 years
13 Participants12 Participants25 Participants
Age, Continuous57 years60 years59 years
Baseline State anxiety (at enrolment)27 units on a scale27 units on a scale27 units on a scale
Baseline Trait anxiety (at enrolment)30 units on a scale27 units on a scale29 units on a scale
Baseline VAS anxiety5 units on a scale5 units on a scale5 units on a scale
Hernia (inguinal/umbilical)
Inguinal hernia
17 Participants14 Participants31 Participants
Hernia (inguinal/umbilical)
Umbilical hernia
1 Participants4 Participants5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
18 Participants18 Participants36 Participants
Region of Enrollment
Denmark
18 participants18 participants36 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
18 Participants18 Participants36 Participants
Surgery (laparoscopic/open)
Laparoscopic
17 Participants13 Participants30 Participants
Surgery (laparoscopic/open)
Open
1 Participants5 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 17
other
Total, other adverse events
0 / 160 / 17
serious
Total, serious adverse events
0 / 160 / 17

Outcome results

Primary

Preoperative Anxiety

The State scale of the State-Trait Anxiety Inventory (STAI). Construct: Current level of anxiety. Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).

Time frame: 60 minutes preoperative

ArmMeasureValue (MEDIAN)
MelatoninPreoperative Anxiety27 score on a scale
PlaceboPreoperative Anxiety28 score on a scale
Secondary

General Well-being and Fatigue

Visual analog scale

Time frame: 24 hours

Secondary

Intraoperative Requirement of Propofol

mg/kg/min

Time frame: intraoperative

Secondary

Intraoperative Requirement of Remifentanil

µg/kg/min

Time frame: intraopeative

Secondary

Perioperative Sleep Quality

Visual analog scale

Time frame: 24 hours

Secondary

Plasma Concentrations of Melatonin

pg/ml

Time frame: baseline, 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, 360 min and 420 min. after melatonin administration.

Secondary

Postoperative Anxiety

State-Trait Anxiety Index

Time frame: at the preoperative interview, 60 minutes prior to surgery and 4 hours postoperatively.

Secondary

Pre- and Postoperative Anxiety

Visual analog scale

Time frame: at the preoperative interview, 60 minutes prior to surgery, 1 and 4 hours postoperatively.

Secondary

Use of Rescue-opioids in the PACU

dose

Time frame: 0-24 hours postoperative

Secondary

Use of Rescue-opioids in the Ward

dose

Time frame: 0-24 hours postoperative

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026